CONFIDENTIAL TREATMENT REQUESTED First Amendment to the Research and Development Collaboration and License AgreementResearch and Development Collaboration and License Agreement • August 9th, 2016 • Compugen LTD • Biological products, (no disgnostic substances)
Contract Type FiledAugust 9th, 2016 Company IndustryThis is the first Amendment (hereinafter “Amendment”) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Muellerstrasse 178, 13353 Berlin, Germany (hereinafter: “BAYER”) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (hereinafter: “Compugen”) effective as of 5 August 2013 (hereinafter: the “Agreement”).
CONFIDENTIAL TREATMENT REQUESTED Second Amendment Agreement to Research and Development Collaboration and License AgreementResearch and Development Collaboration and License Agreement • August 9th, 2016 • Compugen LTD • Biological products, (no disgnostic substances)
Contract Type FiledAugust 9th, 2016 Company IndustryThis Second Amendment Agreement is entered into as of this 27th day of July, 2015 (the “Amendment Date”), by and between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Müllerstraße 178, 13353 Berlin, Germany (“Bayer”) and Compugen Ltd a company formed under the laws of Israel, having a place of business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (“Compugen”). Bayer and Compugen each shall be referred to herein as a “Party” and they shall be referred to together as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED Third Amendment to the Research and Development Collaboration and License AgreementResearch and Development Collaboration and License Agreement • August 9th, 2016 • Compugen LTD • Biological products, (no disgnostic substances)
Contract Type FiledAugust 9th, 2016 Company IndustryThis is the third Amendment (hereinafter “Third Amendment”) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Muellerstrasse 178, 13353 Berlin, Germany (hereinafter: “BAYER”) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 26 Harokmim Street, Holon 5885849, Israel (hereinafter: “Compugen”) effective as of 5 August 2013, as amended on February 5, 2014 and on July 27, 2015 (hereinafter: the “Agreement”).